 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | FSG Social Impact Consultants |
| Street 1: | 500 Boylston Street, Suite 600 |
| Street 2: | |
| City: | Boston |
| Province: | |
| Post Code: | 02116 |
| Country: | United States of America |
| Phone: | (617) 357-4000 |
| Email: | john.kania@fsg.org |
| Web Site: | http://www.fsg.org |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Private sector |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | None |
| Is your organization legally registered in your country: | Yes |
| Organization Reach: | International |
| Organization Description: | |
| FSG is a nonprofit consulting firm specializing in strategy, evaluation, and research, founded in 2000 as Foundation Strategy Group and celebrating a decade of global social impact. Today, FSG works across sectors in every region of the globe — partnering with foundations, corporations, nonprofits, and governments to develop more effective solutions to the world’s most challenging issues. FSG brings together leaders that are hungry to exchange information, to elevate learning and to create collective impact for shared priorities in social change. Working with many of the world’s leading corporations, nonprofit organizations, and charitable foundations, FSG has completed more than 400 consulting engagements around the world, produced dozens of research reports, and published influential articles in Harvard Business Review and Stanford Social Innovation Review among other publications. FSG has a long history of client work in global health across a range of issues, including TB. Currently, FSG is working with a major international foundation to develop and drive a strategy to increase access to affordable second line drugs for MDR TB, working with a wide-ranging group of international stakeholders. As FSG continues to develop and expand its role as an adviser to the global health community, efforts to stem the advance of TB will remain a big part of our focus. |
|
| Total number of staff in your organization: | 51 - 99 |
| Number of full-time staff who are directly involved with TB: | 6 - 10 |
| Number of part-time staff who are directly involved with TB: | 0 |
| Number of volunteers who are directly involved with TB: | 0 |
| What is your organization's annual budget (USD) dedicated to TB? | Unable to disclose amount |
| How did you hear about the Stop TB Partnership: | Involvement in TB control provision |
| Why do you wish join the Stop TB Partnership: | Information on developments within the TB world |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| N/A | |
Geographical Reach | |
| Which country is your headquarters located in: | United States of America |
| Which WHO region is the main focus of your work: | Global |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
India Switzerland United States of America |
Specializations | |
|
Advocacy, communication and social mobilization Research and Development Technical Assistance |
Specializations in Countries | |
| Advocacy, communication and social mobilization | India |
| Advocacy, communication and social mobilization | Switzerland |
| Advocacy, communication and social mobilization | United States of America |
| Research and Development | India |
| Research and Development | Switzerland |
| Research and Development | United States of America |
| Technical Assistance | India |
| Technical Assistance | Switzerland |
| Technical Assistance | United States of America |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
Drug-Resistant TB: FSG is currently working with a major international foundation and other key stakeholders to drive a global effort to expand access to affordable second line drugs for MDR TB. New TB Drugs: FSG is currently working with a major international foundation and other key stakeholders to drive a global effort to expand access to affordable second line drugs for MDR TB. Fundamental Research: FSG contributes to the intellectual capital and thought leadership behind programming for TB, through its client work with funders and implementing organizations. |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | February 23, 2012 |
| Last updated: | June 5, 2012 |